GSK3B and gallbladder cancer: Consistent with previous studies, the results in our study demonstrated that the knockdown of CEP55 downregulated the phosphorylation level of AKT, GSK-3β, and ERK1/2 to inhibit AKT and ERK signaling pathways in gallbladder cancer cells, causing the cascade inactivation of the AKT and ERK signaling networks.